Key Highlights
● Definium climbed to a $35.39 close from $33.27 on November 9.
● DT120 met its goals in two Phase 3 anxiety studies.
● The new drug application is on track for the first half of 2027.
● The company reported about $1.05 billion in cash.
Two trials, one message
Definium Therapeutics (NASDAQ:DFTX), formerly known as MindMed, climbed on Monday, November 9, 2026, rising to a $35.39 close from $33.27 on Friday, according to news reports. The shares edged a little higher after hours, to about $35.48. The Earnings calendar listed the Quarterly Report for after the close, so the regular-session gain came before the formal release.
The focus was DT120, the company's LSD-based orally disintegrating tablet. In its third-quarter update, Definium highlighted that DT120 met its primary and key secondary goals in two Phase 3 studies in generalized anxiety disorder. According to the company's earnings call, the Voyage study of 214 patients showed a 5.4-point improvement versus placebo on the HAM-A anxiety scale at week 12, and the Panorama study of 245 patients showed a 5.1-point improvement. Both results carried p-values below 0.0001, a sign the findings were very unlikely to be due to chance.
Building on an earlier win
The anxiety data followed a positive Phase 3 result in major depressive disorder, the Emerge study, in June. Definium said its new drug application is on track for the first half of 2027, and it reported about $1.05 billion in cash, a sizeable cushion for a company preparing for a possible launch.
Executives sounded confident on the call. Chief executive Rob Barrow said "we have moved beyond demonstrating the promise of DT120 ODT," according to market coverage transcript. Chief commercial officer Matt Wiley said: "The strength and consistency of the DT120 data allows us to plan for launch with increasing clarity and sustained urgency." Chief medical officer Dr. Dan Karlin added: "In each study, a single 100 microgram dose produced rapid and durable improvements in the disorders."
Why a single dose stands out
Generalized anxiety disorder is a common condition marked by persistent, hard-to-control worry. Existing treatments typically involve daily medication and can take weeks to work. A therapy that delivers lasting improvement from a single dose, if confirmed by regulators, would represent a very different treatment model, which helps explain why investors are paying close attention.
Psychedelic-derived medicines also face extra scrutiny, from how sessions are supervised to how regulators weigh safety. Those questions will shape how quickly any approved product could reach patients, and how widely it might be used.
Riding a strong tape
Definium's gain came on a day when nearly everything rose. The Nasdaq Composite surged 673.71 points to 25,253.14, its best day since July 30, and the Russell 2000 rallied 86.71 points to 2,840.81. Falling oil prices, on hopes for a US-Iran peace deal, and a sharp rebound in chip stocks fueled the advance.
Health-care stocks were a mixed bag of company news. Vir Biotechnology (NASDAQ:VIR) and Immunovant (NASDAQ:IMVT) rose on trial successes, while Faeth Therapeutics (NASDAQ:FTH) and Zura Bio (NASDAQ:ZURA) tumbled on disappointing data.
Filing Timeline Takes Focus
The big milestone is the planned new drug application in the first half of 2027. Investors will watch for any updates on the timing of that filing, discussions with the Food and Drug Administration, and the company's commercial preparations, including how treatment sessions might be delivered in practice. Full study presentations at medical meetings could add detail on safety and how long the benefit lasts.
Cash burn will be another focus as launch planning ramps up, though the roughly $1.05 billion balance gives Definium room to operate. On the macro side, Tuesday's October Consumer Price Index is the last Inflation report before the Federal Reserve's December 8-9 meeting, where a rate hike is widely expected.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...